Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634840 | 1.00 | SLC5A2 (0.70) | SLC5A2SLC5A1 | |
| SCHEMBL173842 | 1.00 | SLC5A2 (0.70) | SLC5A2SLC5A1 | |
| SCHEMBL14634839 | 0.94 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL26892301 | 0.83 | SLC5A2 (0.78) | SLC5A2SLC5A1 | |
| SCHEMBL14862842 | 0.83 | SLC5A2 (0.80) | SLC5A2SLC5A1 | |
| SCHEMBL14634764 | 0.83 | SLC5A2 (0.95) | SLC5A2SLC5A1 | |
| SCHEMBL14634761 | 0.83 | SLC5A2 (0.95) | SLC5A2SLC5A1 | |
| SCHEMBL877233 | 0.83 | SLC5A2 (0.95) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL23072082 | 0.82 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL15168697 | 0.82 | SLC5A2 (1.00) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20130310369-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC | 2013-11-21 | — | — | US | disclosed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885 |
| US-20130310369-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | CEL, HTR7, HTR1A | SLC5A2 71/4885SLC5A1 46/4885 |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | SLC5A2 4/4885SLC5A1 5/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | SLC5A2 5/4885SLC5A1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.